Updates are available Correction dated 2022-04-02

Article History

Received: 7 December 2020

Revised: 18 May 2021

Accepted: 17 June 2021

First Online: 20 July 2021

Change Date: 2 April 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00417-022-05621-w

Declarations

:

: The ALTAIR study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines E6: Good Clinical Practice. The protocol was approved by the independent ethics committee or institutional review board at each study site.

: Informed consent was obtained from all individual participants included in the study.

: M.O.: grants and personal fees—AbbVie Japan, Inc., Alcon Pharma K.K. (Japan), Allergan, B.L.J Ltd., Bayer Yakuhin, Ltd. (Japan), Chengdu Kanghong Biotechnology Co., Ltd., Chugai, HOYA, Kowa, Novartis Pharma K.K., Otsuka Pharmaceuticals, Pfizer Pharmaceuticals K.K, Santen Pharmaceuticals Co., Ltd., and Senju Pharmaceutical Co., Ltd., Topcon, during the conduct of the study.A.A.O.: personal fees—Allergan Japan, Astellas Japan, Bayer Healthcare AG, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, Otsuka Pharmaceutical Co., Ltd, and Senju Pharmaceutical Co., Ltd.; grants and personal fees—Bayer Yakuhin Ltd. (Japan), Novartis Pharma KK (Japan), and Santen Pharmaceutical Co., Ltd, during the conduct of the study; and personal fees—AbbVie Japan, Inc., Kowa Co., Ltd., and Mitsubishi Tanabe Pharma Corporation, outside of the submitted work.K.S.: employee—Bayer Yakuhin Ltd., Japan.T.M. and S.-C.C.M.: employees—Bayer AG, Berlin, Germany.K.T.: grants and personal fees—Alcon Japan, Allergan Japan, Bayer Yakuhin, Ltd. (Japan), HOYA, Kowa, Kyowa Kirin Co., Ltd., Nitto Medic, Novartis Pharma, Ono, Otsuka Pharmaceuticals, Santen Pharmaceuticals Co., Ltd., and Senju Pharmaceutical Co., Ltd during the conduct of the study.